Actionable Stock Market Trading Newswire. Built for Traders, by Traders.
All news is property of their respective owners.

Home Newsfeeds BTIG Downgrades Wingstop to Neutral

BTIG Downgrades Wingstop to Neutral

BTIG analyst Peter Saleh downgrades Wingstop (NASDAQ:WING) from Buy to Neutral.

byBenzinga Newsdesk

February 23, 2023

1 minute read

BTIG analyst Peter Saleh downgrades Wingstop (NASDAQ:WING) from Buy to Neutral.

News

Addex Publishes Dipraglurant Data Showing In Vivo Efficacy on Motor and Non-Motor Symptoms of Parkinson’s Disease

By Benzinga Newsdesk

April 4, 3:25 AM

Addex Therapeutics (NASDAQ:ADXN), a clinical-stage pharmaceutical company pioneering allosteric modulation-based drug discovery and development, today announced data showing that dipraglurant could have

ADXN

Tradeweb Markets Q2 EPS $0.47 Beats $0.46 Estimate, Sales $297.14M Miss $298.01M Estimate

By Benzinga Newsdesk

August 3, 7:27 AM

Tradeweb Markets (NASDAQ:TW) reported quarterly earnings of $0.47 per share which beat the analyst consensus estimate of $0.46 by 2.17 percent. This is a 20.51 percent increase over earnings of $0.39 per share from the

USA Compression Partners Q2 EPS $(0.03) Beats $(0.05) Estimate, Sales $171.46M Beat $168.30M Estimate

By Benzinga Newsdesk

August 2, 7:26 AM

USA Compression Partners (NYSE:USAC) reported quarterly losses of $(0.03) per share which beat the analyst consensus estimate of $(0.05) by 40 percent. This is a 70 percent increase over losses of $(0.10) per share from

USAC

Analyst Ratings

Analyst Expectations for Aravive’s Future

By Benzinga Insights

May 25, 11:00 AM

Over the past 3 months, 6 analysts have published their opinion on Aravive (NASDAQ:ARAV) stock. These analysts are…

ARAV

BTIG Downgrades Wingstop to Neutral

Related Posts

Addex Publishes Dipraglurant Data Showing In Vivo Efficacy on Motor and Non-Motor Symptoms of Parkinson’s Disease

Tradeweb Markets Q2 EPS $0.47 Beats $0.46 Estimate, Sales $297.14M Miss $298.01M Estimate

USA Compression Partners Q2 EPS $(0.03) Beats $(0.05) Estimate, Sales $171.46M Beat $168.30M Estimate

Analyst Expectations for Aravive’s Future